The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	MALČÍKOVÁ Jitka RÁZGA Filip JURČEK Tomáš DVOŘÁKOVÁ Dana ŽÁČKOVÁ Daniela TOŠKOVÁ Hana ŠEBEJOVÁ Ludmila ŠMARDOVÁ Jana OLTOVÁ Alexandra VAŇKOVÁ Gabriela JURAČKOVÁ Lenka TRBUŠEK Martin POSPÍŠILOVÁ Šárka MAYER Jiří RÁČIL Zdeněk
Year of publication	2013
Type	Article in Periodical
Magazine / Source	Leukemia & Lymphoma
MU Faculty or unit	Central European Institute of Technology
Citation
Web	http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal
Doi	http://dx.doi.org/10.3109/10428194.2012.762649
Field	Oncology and hematology
Keywords	BCR-ABL1; T315I; chronic myelogenous leukemia; therapy
Attached files	EL_1163539_The_BCR-ABL1.pdf
Description	The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.